02.23.21

Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trials

Source: Asclepix Therapeutics

01.05.21

AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DME

Source: AsclepiX Therapeutics

06.24.20

AsclepiX Therapeutics Announces $35 Million Series A Financing

Source: AsclepiX Therapeutics

11.13.18

AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DME

Source: AsclepiX Therapeutics

View more stories